Composition comprising three
Provided are a mixture of three species of Lactobacillus fermentum strain and Lactobacillus plantarum strain and use thereof. A composition according to one aspect including, as an active ingredient, a mixture of Lactobacillus fermentum strains GB102 and GB103 and Lactobacillus plantarum strain GB104; or a lysate or culture solution thereof, or an extract of the culture solution, can be usefully used for the prevention or treatment of muscle-related disorders or obesity by alleviating the decrease in grip strength induced by aging or reducing the change in intestinal microbial environment induced by aging.
1. A composition comprising:
a Lactobacillus fermentum GB102 strain deposited with Korean Collection for Type Cultures (KCTC) with accession number KCTC 14105BP;
a Lactobacillus fermentum GB103 strain deposited with KCTC with accession number KCTC 14106BP;
a Lactobacillus fermentum GB104 strain deposited with KCTC with accession number KCTC 14107BP;
a Bifidobacterium animalis strain;
a Lactobacillus acidophilus strain; and
auxiliary ingredients;
wherein the auxiliary ingredients comprise Andong yam, adlay, Ganoderma lucidum , inulin, red ginseng , and vitamin B2;
wherein a total amount of the Lactobacillus fermentum GB102 strain, the Lactobacillus fermentum GB103 strain, the Lactobacillus fermentum GB104 strain, the Bifidobacterium animalis strain, and the Lactobacillus acidophilus strain is 10 8 CFU/g to 10 13 CFU/g, and
wherein a total amount of the auxiliary ingredients is 70.20 mg.
2. The composition of claim 1 , wherein the strains are live bacteria or dead bacteria.
3. The composition of claim 1 , wherein the composition is orally administered.
4. The composition of claim 1 , wherein the composition is for anti-aging.
5. The composition of claim 4 , wherein the anti-aging is one or more selected from the group consisting of anti-aging of muscle cells, anti-aging of nerve cells, anti-aging of skin cells, and anti-aging of an intestinal microbial environment.
6. A health functional food for alleviating muscle disorders, comprising the composition of claim 1 as an active ingredient.
7. The health functional food of claim 6 , wherein the composition reduces at least one from the group consisting of joint stiffness, muscle loss, power loss, speed loss, balance loss, endurance loss, and agility loss.
8. The health functional food of claim 6 , wherein the composition causes at least one selected from the group consisting of increased exercise performance, restored muscle coordination, restored mobility and gait, and increased muscle mass and grip strength.
9. The health functional food of claim 6 , wherein the muscle disorders comprises at least one selected from the group consisting of sarcopenia, geriatric sarcopenia, atony, muscular atrophy, muscular dystrophy, disuse muscle atrophy, motor neuron disease, inflammatory myopathy, neuromuscular junction disease, endocrine myopathy, muscle degeneration, myotonia, muscular atrophy with progressive sclerosis, myasthenia gravis, myositis, muscle calcification, muscle ossification, muscle weakness-related disorders, and cachexia.
10. A pharmaceutical composition for treating muscle disorders comprising the composition of claim 1 as an active ingredient.
11. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition reduces at least one from the group consisting of joint stiffness, muscle loss, power loss, speed loss, balance loss, endurance loss, and agility loss.
12. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition causes at least one selected from the group consisting of increased exercise performance, restored muscle coordination, restored mobility and gait, and increased muscle mass and strength.
13. The pharmaceutical composition of claim 10 , wherein the muscle disorders comprise at least one selected from the group consisting of sarcopenia, geriatric sarcopenia, atony, muscular atrophy, muscular dystrophy, disuse muscle atrophy, motor neuron disease, inflammatory myopathy, neuromuscular junction disease, endocrine myopathy, muscle degeneration, myotonia, muscular atrophy with progressive sclerosis, myasthenia gravis, myositis, muscle calcification, muscle ossification, muscle weakness-related disorders, and cachexia.
14. A feed composition comprising the composition of claim 1 as an active ingredient.